JP2005511606A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511606A5
JP2005511606A5 JP2003542164A JP2003542164A JP2005511606A5 JP 2005511606 A5 JP2005511606 A5 JP 2005511606A5 JP 2003542164 A JP2003542164 A JP 2003542164A JP 2003542164 A JP2003542164 A JP 2003542164A JP 2005511606 A5 JP2005511606 A5 JP 2005511606A5
Authority
JP
Japan
Prior art keywords
alkyl
group
aryl
phenyl
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003542164A
Other languages
English (en)
Japanese (ja)
Other versions
JP4491235B2 (ja
JP2005511606A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/035365 external-priority patent/WO2003040118A1/en
Publication of JP2005511606A publication Critical patent/JP2005511606A/ja
Publication of JP2005511606A5 publication Critical patent/JP2005511606A5/ja
Application granted granted Critical
Publication of JP4491235B2 publication Critical patent/JP4491235B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003542164A 2001-11-08 2002-11-05 メラノコルチン受容体調節剤としての新規な１，２，４−チアジアゾリウム誘導体 Expired - Fee Related JP4491235B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33776201P 2001-11-08 2001-11-08
PCT/US2002/035365 WO2003040118A1 (en) 2001-11-08 2002-11-05 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators

Publications (3)

Publication Number Publication Date
JP2005511606A JP2005511606A (ja) 2005-04-28
JP2005511606A5 true JP2005511606A5 (https=) 2006-01-05
JP4491235B2 JP4491235B2 (ja) 2010-06-30

Family

ID=23321888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003542164A Expired - Fee Related JP4491235B2 (ja) 2001-11-08 2002-11-05 メラノコルチン受容体調節剤としての新規な１，２，４−チアジアゾリウム誘導体

Country Status (25)

Country Link
US (4) US7319107B2 (https=)
EP (1) EP1444215B1 (https=)
JP (1) JP4491235B2 (https=)
CN (1) CN100422164C (https=)
AR (1) AR037284A1 (https=)
AT (1) ATE333449T1 (https=)
AU (1) AU2002340372B2 (https=)
BR (1) BR0214023A (https=)
CA (1) CA2466145A1 (https=)
CY (1) CY1105233T1 (https=)
DE (1) DE60213276T2 (https=)
DK (1) DK1444215T3 (https=)
ES (1) ES2268108T3 (https=)
IL (2) IL161830A0 (https=)
MX (1) MXPA04004457A (https=)
MY (1) MY134994A (https=)
NO (1) NO328194B1 (https=)
NZ (1) NZ532884A (https=)
PT (1) PT1444215E (https=)
RS (1) RS51199B (https=)
RU (1) RU2323932C2 (https=)
SI (1) SI1444215T1 (https=)
TW (1) TWI317358B (https=)
WO (1) WO2003040118A1 (https=)
ZA (1) ZA200404487B (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
RU2317292C2 (ru) * 2001-11-08 2008-02-20 Орто-Макнейл Фармасьютикал, Инк. Новые производные 1,2,4-тиадиазола в качестве модуляторов рецепторов меланокортина
US7319107B2 (en) * 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US8460243B2 (en) * 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
US20050187268A1 (en) * 2004-02-23 2005-08-25 Prolexys Pharmaceuticals Inc. Non-peptidyl agents with pHSP20-like activity, and uses thereof
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2005119524A2 (en) 2004-06-04 2005-12-15 Therasense, Inc. Diabetes care host-client architecture and data management system
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US7981146B2 (en) * 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070060988A1 (en) * 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) * 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7981147B2 (en) * 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8527313B2 (en) * 2006-05-15 2013-09-03 Sap Ag Document instantiation triggering a business action
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7976573B2 (en) * 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008027069A1 (en) * 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
USD614303S1 (en) 2008-02-06 2010-04-20 Tearscience, Inc. Eye treatment apparatus
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
EP2278962B1 (en) * 2008-02-21 2014-02-12 Janssen Pharmaceutica N.V. Methods for the treatment of dermatological disorders
US8377925B2 (en) 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
NZ596138A (en) * 2009-04-24 2013-11-29 Janssen Pharmaceuticals Inc Stable topical compositions for 1,2,4-thiadiazole derivatives
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
ES2360783B1 (es) * 2009-10-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011156246A1 (en) 2010-06-11 2011-12-15 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
RU2449997C1 (ru) * 2011-02-15 2012-05-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) 5-амино-3-(2-аминопропил)-[1,2,4]тиадиазолы
EP2628734A4 (en) * 2010-10-15 2014-04-23 Federalnoe G Bydzhetnoe Uchrezhdenie Nauki Inst Fiziol Aktivnikh Veschestv Rossiiskoi Akademii Nauk DERIVATIVES OF 5-AMINO - [1,2,4] THIADIAZOLE
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
WO2014031857A2 (en) 2012-08-22 2014-02-27 Tearscience, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
EP3424558B1 (en) 2013-04-30 2020-07-22 Alcon Inc. Systems for the treatment of eye conditions
WO2016066857A1 (en) 2014-10-31 2016-05-06 Lipotec, S.A.U. Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof
PL3356386T3 (pl) 2015-09-30 2024-08-05 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
US20210169969A1 (en) 2018-04-06 2021-06-10 Leonardus H.T. Van Der Ploeg Compositions for treating kidney disease
CN115381955B (zh) * 2021-05-24 2024-05-17 中国科学技术大学 黑皮质素受体mc5r的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE131373C (https=)
DE1670960A1 (de) * 1967-12-08 1971-02-18 Bayer Ag Verfahren zur Herstellung von salzartigen heterocyclischen Verbindungen
DD131373A1 (de) 1977-06-17 1978-06-21 Juergen Liebscher Verfahren zur herstellung von 2,3-disubstituierten 5-dialkylamino-1,2,4-thiadiazoliumsalzen
JPS6011481A (ja) 1983-06-30 1985-01-21 Nippon Soda Co Ltd １，２，４−チアジアゾ−ル系誘導体及び農園芸用殺菌剤
JPH02173165A (ja) 1988-12-27 1990-07-04 Nippon Soda Co Ltd 防汚剤
US20020103194A1 (en) * 1997-04-30 2002-08-01 Anabella Villalobos Novel muscarinic receptor agonists
EP0805153B1 (en) * 1996-04-30 2001-11-14 Pfizer Inc. Novel muscarinic receptor agonists
TR199903082T2 (xx) * 1997-06-24 2000-07-21 Janssen Pharmaceutica N.V. Anjiogenez inhibit�r� 5-s�bstit�e-1,2,4,-tiadiazolil t�revleri.
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
EP1076648B1 (de) 1998-04-29 2006-07-12 MERCK PATENT GmbH Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
US6294534B1 (en) * 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2000024725A1 (en) 1998-10-26 2000-05-04 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
WO2001055107A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
JP2003527444A (ja) * 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
US6728804B1 (en) 2000-10-27 2004-04-27 Emware, Inc. Remotely reprogrammable communications adapter for providing access to an electronic device
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
RU2317292C2 (ru) * 2001-11-08 2008-02-20 Орто-Макнейл Фармасьютикал, Инк. Новые производные 1,2,4-тиадиазола в качестве модуляторов рецепторов меланокортина
US7435429B2 (en) 2002-02-07 2008-10-14 Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
EP2278962B1 (en) 2008-02-21 2014-02-12 Janssen Pharmaceutica N.V. Methods for the treatment of dermatological disorders
NZ596138A (en) 2009-04-24 2013-11-29 Janssen Pharmaceuticals Inc Stable topical compositions for 1,2,4-thiadiazole derivatives

Similar Documents

Publication Publication Date Title
JP2005511606A5 (https=)
RU2004114208A (ru) Новые производные 1, 2, 4-тиадиазолия в каестве модуляторов рецепторов меланокортина
JP2005511605A5 (https=)
RU2004114214A (ru) Новые производные 1,2,4-тиадиазола в качестве модуляторов рецепторов меланокортина
Kemper et al. Thioridazine-induced torsade de pointes: successful therapy with isoproterenol
RU2374239C2 (ru) Производные арилпиридина
US20100056444A1 (en) Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
JP2004512328A5 (https=)
JP2003528872A5 (https=)
JP2009504748A5 (https=)
JP2006514095A5 (https=)
JP2006516251A5 (https=)
US20230062049A1 (en) Methods of treating alpha adrenergic mediated conditions
US20240139224A1 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
JP2022502387A5 (https=)
Ohtani et al. A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats
WO2003066100A1 (fr) Stimulants de la pousse de cheveux, preparations percutanees et procede de stimulation de la pousse de cheveux
DK2303264T3 (en) METHODS FOR TREATING ALPHA-ADRENERG-MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES
Jain et al. Itraconazole: an effective oral antifungal for onychomycosis.
US10624877B2 (en) Composition and method for treatment of symptoms associated with various skin conditions
AU2017374450B2 (en) Parenteral liquid preparation comprising carbamate compound
EP1051172A2 (en) Method for treating copd
BR112020019577A2 (pt) Combinação farmacêutica tripla compreendendo dabrafenibe, trametinibe e um inibidor de erk
Stehr et al. The effects of levosimendan on myocardial function in ropivacaine toxicity in isolated guinea pig heart preparations
JP2005515199A5 (https=)